An earlier Phase 1 clinical trial of a prototype monovalent dengue-1 DNA vaccine showed the vaccine to be well tolerated and capable of generating good anti-dengue IFNγ T-cell responses, but poor anti-dengue neutralizing antibody responses. This evidence concerns the gene IFNG and dengue disease.